Oculis Raises CHF20M To Advance Topical DME Therapy And Turn Swiss

Icelandic clinical stage biotech Oculis closes CHF20M ($20.3m) series B financing to advance development of its Phase IIb topical DME drug candidate, relocate to Switzerland and beef up its management team.